The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup"

Rhea-AI Summary

The Galien Foundation announced the 2026 Prix Galien USA nominees for four categories: Best Digital Health Solution, Best Medical Technology, Incubators, Accelerators and Equity, and Best Startup. Winners will be honored on October 29, 2026, at the American Museum of Natural History in New York City.

Nominees span leading global companies, funds, academic accelerators and startups, including Hemab Therapeutics (Nasdaq: COAG) in the Best Startup category. According to The Galien Foundation, candidates are evaluated on scientific excellence and potential health impact; for Best Medical Technology, products must have received FDA marketing approval within the last five years.

News Market Reaction – COAG

+0.88%

+0.88% Session close to close

In the Aug 13 session, COAG gained 0.88%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

RA CAPITAL MANAGEMENT, L.P. recorded Net Buying of 72,467 shares in the 90-day insider record. That ...

Analysis

RA CAPITAL MANAGEMENT, L.P. recorded Net Buying of 72,467 shares in the 90-day insider record. That ownership context accompanies the nomination, while low short positioning adds positioning context; the announcement does not change disclosed clinical-stage development risk.

Key Figures

Award cycle: 2026 Prix Galien anniversary: 20 years Awards ceremony: October 29, 2026 +5 more

8 metrics

Award cycle 2026 Prix Galien USA nominees

Prix Galien anniversary 20 years Foundation award history

Awards ceremony October 29, 2026 Prix Galien USA Awards Ceremony

FDA approval window last five years Requirement for Best Medical Technology nominees

Global chapters 16 chapters Prix Galien operating footprint

Countries covered more than 75 countries Prix Galien operating footprint

Foundation launch 1970 Prix Galien established in Paris

Bridges Forum launch 2025 Foundation launched inaugural Prix Galien Bridges Forum

Historical Context

5 past events · Latest: Aug 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 11	Q2 earnings report	Positive	+3.8%	Q2 results highlighted pipeline progress and cash runway into 2029.
Jul 14	Clinical data update	Positive	+9.6%	Phase 2 data showed sustained bleed reduction and FDA-supported Phase 3 progression.
Jul 12	Clinical data update	Positive	+0.0%	HMB-002 data reported zero treated bleeds for 8 of 9 evaluable patients.
Jun 26	Pipeline presentation notice	Neutral	+16.8%	The company announced nine clinical and preclinical updates for the ISTH Congress.
May 27	Conference participation	Neutral	+2.7%	Hemab scheduled a fireside chat at the Jefferies Global Healthcare Conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historical reactions were nonnegative across all five selected events, including one 0% reaction.

Key Terms

fda, leadless pacemaker system, everolimus eluting resorbable scaffold system, transcatheter mitral valve replacement system, +1 more

5 terms

fda regulatory

"must be U.S. Food and Drug Administration (FDA) approved for marketing"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

leadless pacemaker system medical

"AVEIR™ Dual Chamber (DR) Leadless Pacemaker System"

An implantable cardiac device that paces the heart without the traditional insulated wires (leads); it is a small capsule placed directly inside a heart chamber via a catheter, rather than being connected by wires to a pocket under the skin. It matters to investors because it represents a technological shift in cardiac device markets—changing procedural settings, complication profiles, replacement patterns and reimbursement dynamics—factors that can affect manufacturers’ sales, profit margins and adoption rates.

everolimus eluting resorbable scaffold system medical

"Esprit™ BTK Everolimus Eluting Resorbable Scaffold System"

A medical implant used to open and support narrowed blood vessels that combines a temporary, bioresorbable scaffold (a structure that gradually dissolves in the body) with a drug coating—everolimus—that slows unwanted tissue growth. Think of it as a dissolvable bridge that both props open a clogged artery and releases medicine to prevent re-blockage. Investors care because clinical trial results, regulatory approvals, manufacturing scale and reimbursement determine commercial potential and revenue prospects for companies that develop or sell these devices.

transcatheter mitral valve replacement system medical

"SAPIEN M3 Transcatheter Mitral Valve Replacement System"

A transcatheter mitral valve replacement system is an implantable medical device and delivery kit designed to replace a failing mitral heart valve without open‑heart surgery, using a catheter threaded through blood vessels or the heart to position and expand the new valve. It matters to investors because its clinical performance, regulatory approvals, production scale, and reimbursement determine market size, adoption rates, and revenue potential for companies that develop, manufacture, or distribute these less‑invasive alternatives; think of it as fixing a roof through a small hatch instead of tearing the whole roof off.

intravesical system medical

"INLEXZO™ (gemcitabine intravesical system)"

A device or delivery method that places medicine directly into the urinary bladder so the drug acts locally on the bladder lining over a controlled time. Examples include catheters, instilled solutions, or small implantable systems that hold and slowly release medication. This matters to investors because device design, clinical performance, regulatory approval, manufacturing and reimbursement determine commercial potential—similar to how a slow‑release fertilizer targets a single plant rather than spraying an entire garden.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Celebrating 20 Years of Honoring the Digital Breakthroughs, Pioneering Startups, and Ecosystems Driving the Future of Healthcare

NEW YORK, Aug. 13, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, announced today the 2026 Prix Galien USA Award nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup." Winners will be honored during the Prix Galien USA Awards Ceremony on October 29, 2026, at the American Museum of Natural History in New York City.

"Witnessing the incredible momentum in medical technology, digital health, and startup ventures is inspiring," said Kenneth C. Frazier, Co-Chair of the Galien Forum, Prix Galien USA Awards Committee. "As we celebrate two decades of the Prix Galien USA Awards, we look forward to honoring this new class of nominees whose inventive work epitomizes the future of health and our collective commitment to improving lives through scientific brilliance."

Marking two decades of shaping medicine for patients worldwide, The Galien Foundation continues to inspire spirited collaboration between science and industry leaders on the most critical topics in medical technology, entrepreneurship, and equity.

"We applaud this year's remarkable Prix Galien USA nominees as we mark twenty years of excellence in medical technology, digital health, and entrepreneurship," said Bruno Cohen, Chairman of The Galien Foundation. "Their achievements beautifully demonstrate how scientific advancements can transform human lives and improve the wellbeing of our planet."

To qualify, each candidate must demonstrate tremendous potential to improve human health and for "Best Medical Technology" must be U.S. Food and Drug Administration (FDA) approved for marketing within the last five years. Sales data are not considered by the nominating committee in their award nominee selection, only science and health impact.

The following candidates have been selected as the 2026 Prix Galien USA nominees:

Best Digital Health Solution (Nominees)

Accumulus Technologies	Accumulus Platform
AEYE Health	AEYE-DS (AEYE Diagnostic Screening)
Altis Labs, Inc.	Imaging-based Prognostication (IPRO)
Aptar Digital Health	Migraine Buddy: a digital health solution generating insights from user-reported data and continuous biometrics
Ayble Health	Ayble: AI-Enabled Virtual Specialty GI Clinic
Beaconcure	Verify: AI-Enabled Statistical Analysis Platform
Biorce	Aika
Cleerly	Cleerly LABS
Evidation Health	Event-Triggered Flare-State Proteomics Platform and Autoimmune Cohort
Evinova	Unified Trial Solution
Fasikl	Felix NeuroAI Wristband
Gheorg	Mental Health App Democratizing Therapy Support for Children
Helfie AI	Helfie AI
Intellect	Intellect: Clinically Validated AI-enabled Global Mental Healthcare Platform
Life365	CloudCare
Medable	Medable Agentic Clinical Development Platform
MPA	MyPsychAdmin
OpenEvidence Inc.	OpenEvidence
Owkin	K Pro
PHIL Inc.	PHIL Digital Hub & PHIL Direct
RapidAI	Rapid Navigator Pro™
SamaCare	SamaCare Platform
The TeleDentists	The TeleDentists
Welldoc	The Welldoc Platform: Healthcare-Ready AI

Best Medical Technology (Nominees)

Abbott	AVEIR™ Dual Chamber (DR) Leadless Pacemaker System
Abbott	Esprit™ BTK Everolimus Eluting Resorbable Scaffold System
Abbott	TriClip™ G4 System
Alcon	UNITY® Vitreoretinal Cataract System (VCS)
Beyond Air, Inc.	LungFit® PH
Cochlear Limited (Cochlear North America)	Nucleus® Nexa™ System
Cresilon	TRAUMAGEL®
Edwards Lifesciences	Edwards SAPIEN M3 Transcatheter Mitral Valve Replacement System
Establishment Labs Holdings Inc.	Motiva Flora® SmoothSilk® Tissue Expander
Guardant Health	Guardant360® Liquid CDx
Guardant Health	Shield™
Insightec	Exablate® Neuro
Johnson & Johnson	INLEXZO™ (gemcitabine intravesical system)
Johnson & Johnson	Impella 5.5™ with SmartAssist™; Impella CP™ with SmartAssist™
Johnson & Johnson	Shockwave™ C2 Coronary IVL Catheter
Lumicell	LumiSystem™
Lungpacer Medical	AeroPace® Transvenous Diaphragm Neurostimulation System
MediBeacon Inc.	TGFR™ System
Medtronic	Altaviva™ Implantable Tibial Neuromodulation Device
Medtronic	Symplicity Spyral™ Renal Denervation System
MiniMed	MiniMed Go™ System
OUR United Corporation	TaiChiPro®
RefleXion Medical	RefleXion® X1 with SCINTIX® biology-guided radiotherapy

Incubators, Accelerators and Equity (Nominees)

ANDHealth (Australia)	ANDHealth+
Avant Bio	Avant Bio Fund II LP
Calibr-Skaggs Institute for Innovative Medicines	Calibr-Skaggs Drug Accelerator
Cross-Border Impact Ventures	Women's and Children's Health Technology Fund
Deep Knowledge Group (incorporating Deep Knowledge Ventures, Longevity Capital, Deep Knowledge Analytics, Deep Pharma Intelligence and Aging Analytics Agency) (https://www.dkv.global/)	Deep Knowledge Group - DeepTech for Social Good (investment, analytics and ecosystem-building consortium spanning AI, Longevity, BioTech and HealthTech)
Mayo Clinic	Mayo Clinic / Mayo Clinic and Arizona State University Alliance for Health Care Accelerator
McGill Dobson Centre for Entrepreneurship	McGill Dobson Centre for Entrepreneurship
Nucleate	The Activator
PureTech Health	PureTech Health
Start it @KBC	Start it @KBC
Weill Cornell Medicine BioVenture Elab	BioVenture eLab

Best Startup (Nominees)

ADVANCED BIODESIGN

AIVITA Biomedical, Inc.

Algen Biotechnologies, Inc.

Alloy Therapeutics

BigHat Biosciences

Bilix

BioSapien

Callio Therapeutics

Captor Therapeutics

Cellares

CheckUps COVA

Compass Pathways

Concordare Trials

Creative BioTherapeutics

EndoCyclic Therapeutics

EnPlusOne Bio

Faeth Therapeutics

General Oncology

HarborSite

Hemab Therapeutics (Nasdaq: COAG)

Hope Medicine

Iambic

Imaginostics, Inc.

Indapta Therapeutics

INGENIA Therapeutics Inc.

Innorna

Innova Therapeutics

Insilico Medicine

Intrepid Labs

Kapsule

LEAF4Life, Inc.

Leal Therapeutics

Leman Biotech Co., Ltd.

Libera Bio S.L.

LIFEN RESEARCH

Lipidio Pharma

magAssist Co., Ltd.

MAIA Biotechnology, Inc.

Mammoth Biosciences, Inc.

March Biosciences, Inc

Matrisome Bio, Inc.

Mesentech Inc.

META Pharmaceuticals Inc

Metro International Biotech, LLC

MirimGENE

Neurosterix

Noetik

Nona Biosciences

OncoRes Medical Pty Ltd

Outcomes4Me

OverT Bio

Paradigm Therapeutics

Pheast Therapeutics

Prellis Biologics, Inc

ProFound Therapeutics

Protara Therapeutics

Quercis

Regard

Rejuvenate Bio

Repair Biotechnologies, Inc.

ReST Therapeutics, Inc

RISA Labs

Rubedo Life Sciences, Inc.

SandboxAQ

Science Corporation

Sculpta, Inc.

SEED Therapeutics Inc.

Shenzhen ReeToo Biotechnology Co., Ltd.

Spore.Bio

Starton Therapeutics

Strand Therapeutics

Stream Biomedical, Inc.

SURGE Therapeutics

synseer

Tahoe Therapeutics

Transcend Therapeutics

Turbine

Ultrasound AI, Inc.

VarmX

Vascarta Inc.

VCCT Inc.

ViCardia Therapeutics, Inc.

XaTek Inc.

Zucara Therapeutics Inc.

Prix Galien Best Medical Technology, Best Digital Health Solution, Best Incubator / Accelerator / Equity, and Best Startup Committee 2026

Kenneth C. FRAZIER
Committee Chair, Former Chairman & CEO Merck

Roch DOLIVEUX
Honorary CEO, UCB

Dr. Mikael DOLSTEN
Former Chief Scientific Officer & President, Pfizer Research and Development

Alex GORSKY
Former CEO & Executive Chairman, Johnson & Johnson

Penny HEATON
M.D., Global Head, Office of the Chief Medical Officer, Johnson & Johnson

Sheri McCOY
Board of Directors, AstraZeneca, Former CEO, Avon

Joel S. MARCUS
Executive Chairman & Founder, Alexandria

Christophe WEBER,
Healthcare Executive, Former CEO Takeda Pharmaceutical

Elias ZERHOUNI
Former Head of Global R&D, Sanofi

About The Galien Foundation
The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve human health. Its vision is to serve as a catalyst for the development of the next generation of treatments and technologies that will transform medical practice and save lives. Established in Paris in 1970 by Roland Mehl in honor of Galen, the father of medical science and modern pharmacology, the Prix Galien is widely regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

Today, the Prix Galien operates through 16 chapters spanning more than 75 countries across Africa, the Americas, Asia, and Europe. Expansion is currently underway in China, Singapore, and Australia.

In 2025, the Foundation launched the inaugural Prix Galien Bridges Forum and Awards Ceremony at the Nobel Forum in Stockholm, spanning Northern and Southern Europe, Israel, and the Middle East, and the first-ever Patient Summit for Prix Galien USA, reinforcing its commitment to science without borders.

The Nobel Prize and the Prix Galien share a common birthplace in Paris, where Alfred Nobel signed his last will and testament in 1895. However, while the Nobel Prize in Physiology or Medicine recognizes up to three individuals for specific discoveries, the Prix Galien honors the collaborative spirit and multidisciplinary progress that define modern biopharmaceutical innovation.

For more information, visit www.galienfoundation.org.

Follow the Foundation on social media: 
https://www.facebook.com/GalienFoundation/
https://twitter.com/GalienFdn 
https://www.linkedin.com/company/the-galien-foundation/ 

Media Contact: 
Kara Bradley
Finn Partners 
Kara.Bradley@finnpartners.com
646-213-7243

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-galien-foundation-announces-2026-prix-galien-usa-nominees-for-best-digital-health-solution-best-medical-technology-incubators-accelerators-and-equity-and-best-startup-302850770.html

SOURCE The Galien Foundation

FAQ

What did Hemab Therapeutics (Nasdaq: COAG) announce regarding the 2026 Prix Galien USA awards?

Hemab Therapeutics (Nasdaq: COAG) was named a nominee in the 2026 Prix Galien USA Best Startup category. According to The Galien Foundation, this category highlights emerging companies whose scientific work shows strong potential to improve human health and transform medical practice.

When and where will the 2026 Prix Galien USA winners be announced?

The 2026 Prix Galien USA winners will be honored on October 29, 2026, at the American Museum of Natural History in New York City. According to The Galien Foundation, the ceremony marks the 20th anniversary of the Prix Galien USA awards program.

What are the 2026 Prix Galien USA award categories relevant to COAG and other companies?

The 2026 Prix Galien USA includes four categories: Best Digital Health Solution, Best Medical Technology, Incubators, Accelerators and Equity, and Best Startup. According to The Galien Foundation, Hemab Therapeutics (COAG) appears among the nominated startups in the Best Startup category.

How are 2026 Prix Galien USA nominees selected for Best Medical Technology and other categories?

Nominees are chosen based on scientific excellence and potential to improve human health. According to The Galien Foundation, Best Medical Technology candidates must have received FDA marketing approval within the past five years, and sales data are excluded from the nominating committee’s considerations.

What is the Prix Galien and why is it significant for healthcare innovators like Hemab Therapeutics (COAG)?

The Prix Galien is a global award recognizing excellence in scientific innovation to improve human health. According to The Galien Foundation, it is widely viewed as comparable to a Nobel-level honor in biopharmaceutical research, emphasizing collaborative and multidisciplinary advances in medicine.

Which types of organizations were nominated for the 2026 Prix Galien USA Incubators, Accelerators and Equity category?

The 2026 Incubators, Accelerators and Equity nominees include investment funds, academic programs and ecosystem-building platforms. According to The Galien Foundation, organizations such as ANDHealth, Avant Bio Fund II, Mayo Clinic accelerators, Nucleate and others were recognized for supporting health technology and life science entrepreneurship.